Expertise in
1
conditions

Ercole Brusamolino

Pavia, IT 
Expertise in
1
conditions
Pavia, IT 

Overview

Ercole Brusamolino practices practicing medicine in Pavia, Italy.

Mr. Brusamolino is highly rated in 1 condition, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Pavia, Italy
Other Locations
Bologna, Italy
Milan, Italy
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Drugs: R-CHOP or R-bendamustine, Observation, Maintenance Weekly x4, Ibritumomab Tiuxetan + Maintenance, Standard Maintenance
Study Phase: Phase 3

11 Total Publications

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Journal: The Lancet. Oncology
Published: March 08, 2017

Frequently Asked Questions about Ercole Brusamolino

Is Ercole Brusamolino a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Ercole Brusamolino is classified as an Distinguished expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ercole Brusamolino participate in research or clinical trials?

Yes. Ercole Brusamolino has published 11 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Ercole Brusamolino's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Brusamolino's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile